while in the quickly evolving subject of most cancers therapeutics, knowing the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is very important for creating successful solutions. Among the most promising approaches is using in vitro bystander outcome assays, which Engage in a pivotal role in maximizing therapeutic efficacy. These assays,